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INTRODUCTION: Blood production in 
humans culminates in the daily release of 
around 1011 cells into the circulation, mainly 
platelets and red blood cells. All blood cells 
originate from a minute population of hema-
topoietic stem cells (HSCs) that expands and 
differentiates into progenitor cells with in-
creasingly restricted lineage choice. Charac-
terizing alternative splicing events involved 
in hematopoiesis is critical for interpreting 
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the effects of mutations leading to inherited 
disorders and blood cancers and for the ra-
tional design of strategies to advance trans-
plantation and regenerative medicine.
RATIONALE: To address this, we explored 
the transcriptional diversity of human blood 
progenitors by sequencing RNA from six 
progenitor and two precursor populations 
representing the classical myeloid commit-
ment stages of hematopoiesis and the main 
lymphoid stage. Data were aligned to the hu-
man reference transcriptome and genome to 
quantify known transcript isoforms and to 
identify novel splicing events, respectively. 
We used Bayesian polytomous model selec-
tion to classify transcripts into distinct ex-
pression patterns across the three cell types 
that comprise each differentiation step.
RESULTS: We identified extensive transcrip-
tional changes involving 6711 genes and 
10,724 transcripts and validated a number of 
these. Many of the changes at the transcript 
isoform level did not result in significant 
changes at the gene expression level. More-
over, we identified transcripts unique to each 
of the progenitor populations, observing en-
richment in non–protein-coding elements 
at the early stages of differentiation. We dis-
covered 7881 novel splice junctions and 2301 
differentially used alternative splicing events, 
enriched in genes involved in regulatory pro-
cesses and often resulting in the gain or loss 
of functional domains. 
Of the alternative splice 
sites displaying differen-
tial usage, 73% resulted 
in exon-skipping events 
involving at least one 
protein domain (38.5%) 
or introducing a premature stop codon 
(26%). Enrichment analysis of RNA-binding 
motifs provided insights into the regulation 
of cell type–specific splicing events.
To demonstrate the importance of spe-
cific isoforms in driving lineage fating 
events, we investigated the role of a tran-
scription factor highlighted by our analy-
ses. Our data show that nuclear factor I/B 
(NFIB) is highly expressed in megakaryo-
cytes and that it is transcribed from an un-
annotated transcription start site preceding 
a novel exon. The novel NFIB isoform lacks 
the DNA binding/dimerization domain and 
therefore is unable to interact with its bind-
ing partner, NFIC. We further show that 
NFIB and NFIC are important in mega-
karyocyte differentiation.
CONCLUSION: We produced a quantitative 
catalog of transcriptional changes and splic-
ing events representing the early progeni-
tors of human blood. Our analyses unveil a 
previously undetected layer of regulation af-
fecting cell fating, which involves transcrip-
tional isoforms switching without noticeable 
changes at the gene level and resulting in the 
gain or loss of protein functions. ■ 
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Overview of methodology. RNA-sequencing reads from human blood progenitors [opaque 
cells in (A)] were mapped to the transcriptome to quantify gene and transcript expression. 
Reads were also mapped to the genome to identify novel splice junctions and characterize 
alternative splicing events (B). 
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Blood cells derive from hematopoietic stem cells through stepwise fating events. To
characterize gene expression programs driving lineage choice, we sequenced RNA from
eight primary human hematopoietic progenitor populations representing the major
myeloid commitment stages and the main lymphoid stage. We identified extensive cell
type–specific expression changes: 6711 genes and 10,724 transcripts, enriched in
non–protein-coding elements at early stages of differentiation. In addition, we found
7881 novel splice junctions and 2301 differentially used alternative splicing events, enriched
in genes involved in regulatory processes. We demonstrated experimentally cell-specific
isoform usage, identifying nuclear factor I/B (NFIB) as a regulator of megakaryocyte
maturation—the platelet precursor. Our data highlight the complexity of fating events in
closely related progenitor populations, the understanding of which is essential for the
advancement of transplantation and regenerative medicine.
H
ematopoiesis has been extensively studied
as a paradigm of stem cell biology and
development (1). Hematopoietic stem cells
(HSCs) and their progeny have been used
to pioneer stem cell therapies for malig-
nant and nonmalignant hematological diseases
(2), and the successful transplantation of genet-
ically repaired HSCs is at the forefront of regen-
erative medicine in primary immune deficiency
and severe combined immunodeficiency (3, 4).
HSCs reside in the bone marrow and can undergo
asymmetric cell division (5), thereby generating
an identical copy and a multipotent progenitor
cell (MPP). MPPs have the ability to generate all
hematopoietic cell types but are incapable of in-
definite self-renewal and engraftment (6, 7). This
process of expansion, differentiation, and matu-
ration culminates in the daily release of up to 1011
newly formed cells into the circulation, mainly red
blood cells (RBCs) and platelets (8, 9). The mo-
lecular mechanisms driving hematopoiesis have
been classically understood as a cascade of gene
expression programs propelled by transcription
factors (TFs) (10) that direct lineage commitment
and maturation by the coordinated regulation
of gene transcription. Studies of hematological
malignancies and model organisms (1) have iden-
tified many of the critical genes and mechanisms
regulating hematopoietic development. Owing to
species-specific differences, model organisms only
contribute partially toward the detailed character-
ization of transcriptional cascades regulating hu-
man hematopoiesis (11–13).
Genome-wide transcriptional profiling of hu-
man hematopoietic progenitor populations has
identified several transcriptional networks co-
ordinating blood formation (14). However, gene
expression data sets using whole-genome expres-
sion arrays only produce an incomplete assess-
ment of the full repertoire of transcript isoforms
that underpin the fating and expansion of pro-
genitor cells (14–16). Alternative splicing is a
widespread posttranscriptional process in eu-
karyotic organisms, wherein multiple distinct
transcripts are produced from a single gene (17).
Analysis of RNA sequencing (RNA-seq) has shown
that alternative splicing is used in up to 94%
of human multiexonic genes (18, 19), often in a
tissue- and developmental stage–specific man-
ner (18, 20, 21).
Alternative splicing has an important role in
disease, with 15% of disease-causing mutations lo-
cated within splice sites and more than 20% of
missensemutations lyingwithin predicted splicing
elements (22). Studies have also revealed that
somatic mutations of splicing factor genes occur
frequently in hematological cancers, including
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myelodysplasia and chronic lymphocytic leukemia
(23–25). Thus, knowledge of cell type–specific alter-
native splicing and transcript isoform usage is
required to interpret the consequences of genetic
variation and to inform strategies for therapeutic
intervention based on gene repair.
Results
Deep transcriptomes of human
hematopoietic progenitors
We used fluorescence-activated cell sorting (FACS)
of umbilical cord blood (CB) mononuclear cells
to obtain highly purified populations of HSCs
and five progenitor cells [MPP, CLP (common
lymphoid progenitor), CMP (common myeloid
progenitor), GMP (granulocyte monocyte pro-
genitor), and MEP (megakaryocyte erythrocyte
progenitor)]. In addition, erythroblasts (EBs) and
megakaryocytes (MKs), the nucleated precursors
of RBCs and platelets, were obtained by in vitro
differentiation of CB CD34+ cells (Fig. 1A and
fig. S1). For simplicity, we address all eight types
of cells as progenitors.
We sequenced 25 polyadenylated [poly(A)+]
RNA samples, yielding a total of 2.4 × 109 uniquely
aligned reads, ranging from 36 × 106 to 150 × 106
reads per sample (table S1). We used a Bayesian
framework implemented in MMSEQ (26) to quan-
tify gene and transcript expression by aligning
reads to the transcriptome (Fig. 1B). Transcript
usage ratio, the proportion of a gene’s expres-
sion contributed by each of its transcripts, was
also estimated (Fig. 1C). The latter provides an al-
ternative to assessing differential transcript usage,
which is less sensitive to depth of coverage and
data normalization. To validate MMSEQ tran-
script expression estimates, we purified 16 ad-
ditional samples, representing five cell types, and
performed quantitative reverse transcription
polymerase chain reaction (RT-qPCR) using the
Fluidigm BioMark HD system for 36 transcript-
specific assays. Linear regression between RNA-
seq and RT-qPCR expression estimates indicated
high reproducibility in biological replicates (R2 =
0.70) (fig. S2 and table S2).
We confirmed the identity of each cell popu-
lation by assessing the expression patterns of
a set of well-characterized TF genes that are
essential for lineage commitment (Fig. 2A and
fig. S3) (1, 27). For instance, EBF1 expression peaks
in CLPs, as expected from its role in B cell devel-
opment (28). Moreover, the estimated gene expres-
sion of GATA1 and GATA2 reflects their switch in
the differentiation of MEPs to EBs and MKs (29).
Classification of differential expression
patterns during lineage commitment
To assess differential expression during hemato-
poietic lineage commitment at each branching
point, such that all possible patterns of expression
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Fig. 1. Transcriptional atlas of hematopoietic progenitors and precursors. (A) Schematic
representation of the current model of hematopoietic cell ontogeny and samples used in this
study. Established ontological relationships are represented as solid lines; emerging ontological
relationship are represented as dotted lines. A simplified representation of mature cells is shaded.
Antigens used for selecting each population are also indicated. The bone marrow–residing com-
ponents are the HSC (light blue), MPP (dark blue), lymphoid-primed MPP (LMPP), CLP (light
green), CMP (dark green), GMP (light red), MEP (red), EB (light orange), and MK (orange). The
blood-residing components are platelets (P), erythrocytes (E), neutrophils (N), eosinophils (Eo),
monocytes (M), and lymphocytes (L). (B) Data analysis strategy. Reads were mapped to the
transcriptome to quantify expression at the gene and transcript levels as well as the transcript
proportion (defined as the fraction of gene expression level from a given transcript). Comple-
mentary to that, reads were mapped to the genome to identify novel splice junctions and sites
where alternative splicing occurs. (C) Schematic highlighting the difference between assessing
differential expression by looking at transcript expression or transcript proportion.
RESEARCH | RESEARCH ARTICLE
changes are considered, we used MMDIFF (30)
to perform Bayesian polytomous model selection
between the five possible modes of expression
change involving three cell types (see mate-
rials and methods for further details and sig-
nificance thresholds; Fig. 2B). This methodology
identifies, for example, transcripts that are
down-regulated during the transition from CMP
to GMP but retain similar expression between
CMP and MEP.
Across all fating events, we detected 6711 genes,
10,724 transcripts, and 7017 transcript usage ra-
tios with significant differences at least at one of
the branching points (Fig. 2B). In total, we de-
tected transcriptional changes per cell type in 22
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Fig. 2.Transcriptional changes at lineage commitment events. (A) River plot
representing gene expression levels across cell types for key TFs required for
lineage commitment. Line width represents expression level in log2(FPKM + 1)
normalized to the highest expression per gene across cell types. The relative
changes in gene expression recapitulate the current understanding of the role
of these TFs in hematopoietic differentiation. (B) Summary of the number of
transcriptional classes—genes, transcripts, and transcript proportions—changing
at each lineage commitment point. Bayesian polytomous analysis was used to
classify these three quantities into five possible models (top to bottom): NULL
model (no change), three single models (only one cell type different), and a
FULL model (all three estimates differ). The number of events up- or down-
regulated was tallied only when the change occurred in at least two samples
at each branching event with an expression FPKM > 1. (C) Cell-specific
enrichment of protein-coding and non–protein-coding biotypes in up- and
down-regulated transcripts for the polytomous models at each branching
event. (D) Heatmap of expression of lineage-specific transcripts. Polytomous
analysis was used to identify genes that were expressed significantly higher in
a given cell type relative to all others.Top 20 highest scoring transcripts based
on the posterior probability of the model are displayed. The colors along the
left axis reflect whether the gene is protein-coding (green) or otherwise (lilac).
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to 33% of the 20,459 genes expressed across our
data set [defined as expression level ≥ 1 fragment
per kilobase of transcript per million fragments
mapped (FPKM) in at least two samples].
Changes at the transcript level did not imply
measurable differences at the gene level. The
overlap between sets of differentially expressed
transcripts (at the transcript and usage ratio
levels) and of the genes they belong to was low,
ranging from 0 to 35% (fig. S4). The extent of
overlap did not increase when the threshold
applied to ascertain expression (that is, FPKM
≥ 1) was relaxed. Our analysis strategy high-
lights the advantages of using RNA-seq for as-
sessing the richness of changes in expression at
gene and transcript levels compared to probe-
based technologies.
Of the 54,386 transcripts expressed at an
FPKM ≥ 1 in at least two samples, 28,563 (52.5%)
were protein-coding. The second and third most
abundant classes were transcripts with retained
introns [8661 (15.9%)] and processed transcripts
without open reading frames [8140 (15.0%)]. As-
sessment of the transcript biotypes of differen-
tially expressed transcripts revealed that some
modes of expression, at specific branching points,
were significantly enriched for non–protein-coding
isoforms (Fig. 2C and table S3). For example,
during the HSC-to-MPP transition, transcripts
up-regulated in HSCs were enriched for non–
protein-coding biotypes, such as large intergenic
noncoding RNAs (lincRNAs) [false discovery
rate (FDR) = 0.043], whereas transcripts with sim-
ilar expression in both cell types were enriched
for protein-coding biotypes (FDR = 0.014). In con-
trast, differentially expressed transcripts at the
terminal differentiation stage (MEP to EB or MK
branching point) were enriched for transcripts
with protein-coding biotypes (FDR <0.016). These
results suggest that a proportion of the regula-
tion of lineage commitment, in the early stages
of hematopoiesis, involves non–protein-coding
elements and that lincRNAs may counteract
differentiation programs, as observed in embry-
onic stem cells (31).
Cell type–specific genes and transcripts
Having evaluated expression patterns for genes
differentially expressed between cell types at a
branching point, we next focused on those genes
and transcripts that were more highly expressed
in one given cell population while displaying sim-
ilar levels of relatively low expression in all other
seven cell types (see materials and methods).
These cell type–specific genes or transcripts are
likely to be important in conferring cellular
identity (Fig. 2D and tables S4 and S5). Using
conservative thresholds on the posterior proba-
bility and the extent of differential expression
(see materials and methods), we identified be-
tween 6 (for MPP) and 631 (for EB) genes that
were cell type–specific. We tested whether our
cell type–specific gene sets were able to discrim-
inate between cell populations in two microarray
atlases of gene expression in human hematopoi-
esis (14, 16), achieving high concordance (fig. S5,
A to D). The number of cell type–specific tran-
scripts ranged between 19 for MPPs (belonging
to 18 genes) and 1807 for EBs (belonging to 1141
genes). The low number of cell type–specific tran-
scripts inMPPs is consistent with the small num-
ber of transcripts we identified as up-regulated
in this cell type (Fig. 2B). Thus, MPP displayed
not only a lower number of up-regulated genes
compared to HSCs, CMPs, and CLPs but also an
overall lower number of cell-specific transcripts,
suggesting a less distinct transcriptional iden-
tity of MPPs compared to other progenitor cells.
Consistent with our findings at branching
events, cell type–specific gene and transcript
sets show different patterns of enrichment of
biotypes [GeneOntology (GO) term enrichment is
shown in tables S6 and S7]. Non–protein-coding
biotypes were overrepresented in HSC-specific
transcripts (FDR = 1.48 × 10−3), whereas protein-
coding transcripts were significantly enriched
among transcripts specific in cells at termi-
nally differentiated stages (EBs: FDR < 1.00 ×
10−60; MKs: FDR = 1.96 × 10−55).
These cell-specific genes may play important
roles in determining cell identity and prolif-
eration of the different mature blood cells. We
tested the hypothesis that these genes are di-
rectly implicated in mature cell differentiation
and proliferation by overlapping these sets with
genes harboring variants associated with RBC
(32) and platelet (33) quantitative traits through
genome-wide association studies. Genes near loci
associated with platelet count and volume were
enriched in the MK-specific gene set (FDR = 1.7 ×
10−8). In contrast, genes in loci associated with
RBC count, RBC volume, and hemoglobin con-
centration were not enriched in the EB-specific
gene set (FDR = 0.42) or in any other cell-specific
set. This suggests that the regulation of platelet
production is primarily intrinsic to MKs, where-
as RBC production is regulated by mechanisms
extrinsic to the erythroid lineage.
Our data add to the repertoire of genes and
transcripts associated with cell identity in early
and late stages of cell development in hemato-
poiesis, informing downstream examination of
the role of transcriptional isoforms expressed in
each cell population and their changes at each
lineage commitment event.
Identification and characterization of
unannotated splice junctions
Owing to their low abundance and anatomical
compartmentalization in the bone marrow, blood
progenitor cells are systematically underrep-
resented in existing transcript sequence data-
bases. We analyzed an average of 137 million
aligned reads per sample obtained across the
25 samples (table S1 and Fig. 1B) to explore the
magnitude of unannotated splice junctions in
human hematopoietic progenitors. We inter-
sected splice junction calls from three splice-
aware aligners (fig. S6) and required the splice
junction to be observed in at least two samples.
A total of 159,495 unique splice junctions were
detected, of which 29,736 were not annotated in
Ensembl v70. We categorized these unannotated
splice junctions into four classes, depending
on whether their donor and acceptor sites were
annotated within Ensembl (Fig. 3A). For 8382
(28.2%) junctions, both donor and acceptor sites
were known but not the splicing pattern, whereas
8112 (27.3%) and 8321 (28.0%) splice sites in-
cluded unannotated splice donors or acceptors.
Last, 4921 (16.5%) splice events had both donor
and acceptor sites unannotated. The frequency
of the four different categories of splicing events
did not differ among the eight cell populations
(Fig. 3A).
To characterize the 29,736 putative unan-
notated splice junctions, we investigated their
splice site probability scores, degree of conser-
vation, and coding potential. Splice site prob-
ability scores (34) for unannotated splice sites
were similar in known and unannotated donor
sites (>0.90, fig. S7). We observed that conserva-
tion scores for exonic regions with unannotated
splice sites were higher (mean, 0.28) than for
intronic regions in the same splice sites (mean,
0.20; P < 2.2 × 10−16, Wilcoxon rank sum test;
fig. S8). Last, the protein-coding potential of the
unannotated exons was assessed with the fre-
quency of stop codons in all three reading frames
for both directions, within a 100–base pair (bp)
window around the splice sites. A similar distribu-
tion of coding potential was identified in unanno-
tated and annotated exons, with both containing
an average of 1.2 fewer stop codons than the
equivalent intronic regions (fig. S9).
To identify novel splice junctions, we com-
pared the unannotated splice junctions to splice
junctions identified in the University of Califor-
nia Santa Cruz (UCSC) expressed sequence tag
(EST)/mRNA data set and in the poly(A)+ RNA-
seq data set from 16 human tissues in Illumina
BodyMap 2.0 (35). In total, 73.5% of our unanno-
tated events were detected in these external data
sets, with 23.0% detected in UCSC EST/mRNA
data and 72.0% in our reanalysis of the BodyMap
2.0 data set (fig. S10). The remaining 7881 (26.5%)
splice junctions were specific to our data set
(hereafter called novel). Analysis of novel splice
junctions revealed a higher proportion of the
noncanonical splicing motif GC-AG (2.2 and
7.3% in unannotated and novel, respectively)
compared to annotated sites (0.9%, fig. S11).
Whereas both the GT-AG and GC-AG splice sites
are processed by the canonical U2-type spliceo-
some, GC-AG splice sites tend to be alternatively
spliced (36).
We calculated Shannon’s entropy (37) for the
three classes of splice junctions: annotated, un-
annotated, and novel (Fig. 3B). A lower entropy
distribution in the novel splice junction set in-
dicates that these tend to be population-specific
events when compared to the unannotated splice
junctions present in BodyMap 2.0 data or all
annotated junctions (P < 2.2 × 10−16, Wilcoxon
rank sum test; fig. S12). Enrichment analysis of
genes containing novel splice junctions highlighted
GO terms related to cell cycle, DNA metabolism,
and RNA processing (FDR< 5.0 × 10−17; table S8),
suggesting that these novel splice junctions may
alter the function of genes involved in critical
cellular processes.
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Fig. 3. Cell type–specific splicing and RNA-binding motif enrichment
in hematopoiesis. (A) Distribution of splice junction definition, absolute
count, and cell type–specific fractions within unannotated splice junctions.
Blue: annotated exons and junctions; red: unannotated exons and junc-
tions. (B) Cell type specificity of known, unannotated, and novel splice
junctions measured with Shannon’s entropy (37). Lower entropy indicates
that splice junctions are observed in fewer cell types. (C) Region-specific
patterns of RNA-binding protein motifs around spliced-in and spliced-out
DSU cassette exons.The enrichment or depletion of motifs in three regions:
the 300-bp intronic region adjacent to the upstream of the 5′ splice site (blue),
the exonic region of the cassette exon (orange), and the 300-bp intronic
region adjacent to the downstream of the 3′ splice site (green). The heat-
maps present significant enrichment (yellow) or depletion (red) in −log10
P value, FDR < 0.05.
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Our results suggest that a number of the un-
annotated and novel splice junctions are in-
deed functional and used in a cell type–specific
manner on the basis of their splice probabil-
ity, conservation score, coding potential, and
entropy.
Validation of novel splice junctions
We used PCR to independently validate 23 of
the novel splice junctions. The PCR assays (table
S9) performed on five samples showed >90%
concordance rate (105 of 115 reactions; figs. S13
to S16 and table S10). We performed additional
sequencing of poly(A)+ transcripts from sample
MK_3 using the PacBio RS sequencing plat-
form, which enables sequencing of full-length
transcripts and overcomes the limitations of
transcriptome assembly on the basis of short Il-
lumina reads (38). PacBio sequencing yielded
67,110 reads identified as full-length molecules
(originating from individual RNA transcripts)
ranging between 322 and 13,170 bp in length
(median, 2272 bp). These were further combined
into 35,663 consensus sequence clusters—transcript
structures (see materials and methods). Two novel
splice junctions validated by PCR in MKs were
also observed within the PacBio data set (fig.
S15). Using these data, we investigated the tran-
scriptional context of the novel splice junctions
in MKs. Visual inspection of the PacBio align-
ments indicated that a number of novel splice
junctions are part of full-length transcripts, in-
cluding a previously unobserved intergenic locus
on chromosome 12 and an antisense transcript
within an annotated protein-encoding region in
the GNG12 locus (fig. S15).
Of the 94,423 splice junctions with 10 or more
Illumina reads in MK_3, 54% were supported
by PacBio data. In contrast, 7% (66 of 956) of
novel and 11% (773 of 7234) of unannotated splice
junctions identified in MK_3 were recapitulated
in the PacBio data set. We used the annotated
splice junctions to estimate the probability of
detection by PacBio as a function of read depth
and transcript length. The observed validation
rates of unannotated and novel junctions, after
accounting for read depth, would be consistent
with the majority of these junctions originating
from transcripts less than 300 bp in length [fig.
S17 and (39)]. Notwithstanding PacBio’s lower
depth of sequencing and other unaccounted
technical aspects, this analysis provides support
to the idea that a large fraction of novel splicing
events involve very short transcripts not cap-
tured by PacBio.
Differential usage of alternative
splice junctions
To investigate the prevalence of cell type–specific
alternative splicing, we identified 42,001 splice
junction sets where two or more splice junctions
shared either the donor or the acceptor sites.
Of these, we focused on the 20,924 (49.8%) junc-
tions that contained only two splicing alterna-
tives and were detected in at least two biological
replicates. To determine whether an alternative
splice site displays differential splicing usage
(DSU) [that is, the relative contribution of
splicing alternatives (usage proportion) differs
between a given cell type and the average pro-
portion across all other cell types], we fitted
a beta-binomial model and established statis-
tical significance using a likelihood ratio test.
The beta-binomial model accounts for the
overdispersion—beyond the expected binomial
variance—present in the data. It is an extension
to the binomial model (that is, logistic regres-
sion) and is akin to using a negative binomial dis-
tribution to model overdispersed counts data.
This analysis identified 2301 DSU sets (FDR < 0.1).
The number of DSU events ranged between 4
for HSC and 1034 for CLP (table S11 and figs.
S14, S18, and S19). The DSU set was enriched with
novel splice junctions compared to all junctions
(P = 4.39 × 10−7, c2 test).
To better characterize the biological relevance
of cell type–specific DSU, we classified splicing
events according to their transcriptional conse-
quences: 73.4% lead to exon skipping events,
8.3% of junctions have an alternative 3′ accep-
tor, and 6.2% have an alternative 5′ donor; 12.1%
of events could not be annotated by using the
reference transcriptome (fig. S20). Although un-
annotated, the length distribution of this frac-
tion suggests that the majority is composed of
exon skipping events (fig. S20).
In the alternative spliced regions displaying
DSU, 26.1% contained a premature stop codon
and 38.5% contained at least one predicted pro-
tein structure or domain, therefore resulting in
gain or loss of protein functions. No one type of
domain was significantly overrepresented in
the DSU set. Of the alternative acceptor sites
displaying DSU, 39% (84 of 216) resulted from
a 3-bp shift in the alternative acceptor sites
(fig. S21, left panel), displaying a NAGNAG motif
(40) (fig. S21, right panel). This motif maintains
the translation frame and may introduce a sin-
gle amino acid insertion or a substitution (fig.
S22). The 2301 DSU events could be assigned
to 1704 genes. GO enrichment analysis of these
genes indicates that these genes may be directly
involved in the regulation of transcription and
splicing (table S12).
We validated 11 DSU events (4 novel and 7
known events) by using PCR (figs. S14, S15, and
S23). Densitometry estimates of the percentage
spliced-in (PSI) of these PCRs correlates with
the PSI estimated from the RNA-seq data (n =
26, R2 = 0.78, fig. S24). In addition, we validated
a novel DSU in nuclear factor I/B (NFIB) (see
below and Fig. 4A) and a DSU event in GFI1B
(39). In CMPs, EBs, and MKs, the DSU event
in GFI1B results in an alternatively spliced-out
exon 4 that encodes for two Zn finger domains
critical for megakaryopoiesis (39). Overall, the
DSU analysis confirms alternative splicing as an
additional key mechanism through which fun-
damental processes during hematopoiesis are
regulated.
RNA-binding motif enrichment in DSU
Alternative splicing is regulated by trans-acting
splicing factors that recognize cis-acting sequences
in exons or introns, to promote or suppress the
assembly of the spliceosome at the adjacent
splice site. We therefore investigated the mo-
lecular regulation of cell-specific alternative
splicing by examining the sequences around
alternatively spliced exons. We used 102 recently
described RNA-binding motifs of 80 human
RNA-binding proteins (41) to identify sets of
motifs significantly enriched or depleted in the
regions surrounding DSU junctions (table S13).
Of the 80 RNA-binding proteins with known
binding motifs, 59 were expressed in our data
with FPKM > 1 and displayed variable cell type
specificity (fig. S25). RNA-binding motif enrich-
ment analysis was performed on cassette exons
and proximal intronic regions. The patterns of
enrichment and depletion, in addition to the
identity of the motifs, varied widely across cell
types (Fig. 3C).
The proteins BRUNOL, SRSF, and TIA1 and
the HNRNP (heterogeneous ribonucleoprotein)
family of proteins are known to regulate tissue-
specific splicing (42). The patterns of enrichment
and depletion in our data set for these proteins
suggest that their role in regulating tissue-specific
splicing also extends to hematopoietic cells (Fig.
3C). For example, we identified that the motifs
of the HNRNP protein family, which typically
bind to exonic splicing silencers (43), were en-
riched in exonic regions of MPPs and MEPs that
are spliced out.
Novel isoform of NFIB
regulates megakaryopoiesis
To investigate the impact of different transcript
isoforms in a biological system, we focused our
attention on the role of two TFs in megakar-
yopoiesis, NFIB, described below, and GFI1B
(39), as an example of how our analysis informs
the interpretation of patient sequencing data.
NFIB was identified at the MEP/EB/MK branch-
ing point (fig. S26), containing a novel MK-specific
DSU event (FDR < 0.05). The role of NFIB has
been extensively studied in lung maturation, the
nervous system (44), and epithelial stem cell de-
velopment (45). TheNFI family of TFs, constituted
by four members (A, B, C, and X), has previously
been implicated in regulating hematopoiesis, with
Nfix identified as functional in murine HSCs and
progenitors (46) and NFIA implicated in human
erythropoiesis (47). NFIC has been observed as
being differentially expressed between MKs of
fetal and postnatal origin (48). In addition, NFIB
has been identified as one of the TFs down-
regulated in the HSC-to-MPP transition (49). How-
ever, its role in the later stages of hematopoiesis
has remained unexplored.
By examining genomic alignments, we iden-
tified a novel NFIB transcript (chr9:14,179,779–
14,214,332 bp) and annotated the position of the
transcription start site (TSS) in the novel first
exon. The isoform that results from this novel
transcript was primarily expressed in HSCs and
MKs and was only present in white blood cells
in the BodyMap 2.0 data set, whereas the canon-
ical isoform is widely expressed across other
BodyMap 2.0 tissues. The novel TSS lies in a region
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of open chromatin in primary MKs (50) that is
occupied by the TFs MEIS1 (this study), FLI1,
GATA1, and SCL/TAL1, but not GATA2 or
RUNX1 (51). The TSS is also marked by the
promoter mark H3K4me3 in MKs (fig. S27). We
validated the novel TSS by 5′-RACE RT-PCR and
observed multiple PacBio reads supporting it
(Fig. 4A). Western blotting confirmed the pres-
ence of the protein encoded by the novel short
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Fig. 4. A novel isoform of the TF NFIB regulates
megakaryopoiesis. (A) A novel TSS and a novel
exon ofNFIBwere detected by using RNA-seq (blue)
and validatedby using 5′-RACE [rapid amplification of
complementary DNA (cDNA) ends] PCR (red) and
PacBio sequencing (green). Ensembl annotated tran-
scripts are in black. (B) Cartoon representation of
the short and long isoforms of NFIB (NFIB-S and
NFIB-L) highlighting the functional domains. (C)
Western blot (WB) for NFIB, NFIC, and tubulin in
MKs, EBs, and monocytes (M) confirms that NFIB-S
is predominantly expressed in MKs (* is either the
protein product of one of the shorter transcripts of
NFIB observed in the 5′-RACE or unspecific). (D) Co-
immunoprecipitation of overexpressed combinations
ofNFIC-HA togetherwithTAP [Flag plusCREB (cyclic
AMP response element–binding protein)–binding
protein]–taggedNFIC, NFIB-L, andNFIB-S.The upper
panel was probed with anti-NFIC antibodies, showing
both NFIC TAP–tagged (upper band) and NFIC-HA–
tagged (lower band); note the absence of NFIC-HA
in lane 4, showing lack of interaction between NFIC
and NFIB-S. The lower panel was probed with anti-
Flag antibody (part of the TAP tag), showing the im-
munoprecipitated NFIC (lane 2), NFIB-L (lane 3),
and NFIB-S (lane 4) (see also figs. S30 and S31). (E)
Flow cytometry dot plots of CD41a andCD61 staining
of megakaryocyte cultures at day 10 after infection
with shRNA of control, NFIB, and NFIC.The propor-
tions of double-positive [upper right (megakaryocytic)]
versus double-negative [lower left (undifferentiated)]
cells decreased relative to control shRNA by silencing
either NFIB or NFIC. (F) Overexpression of NFIC or NFIB-S led to a higher proportion of
megakaryocytic cells relative to NFIB-L or control. CD41a and CD42b double-positive MKs
in cultures at day 10 after infection. The y axis is the probit proportion of double-positive
MKs after adjusting for batch effects.
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isoform, NFIB-S, as the major isoform in MKs
(Fig. 4B and fig. S28), whereas the longer isoform
encoded by the canonically spliced transcript
could not be detected.
NFIB is known to bind DNA preferentially as
a homodimer or a heterodimer in combination
with other NFI family members (52). Because
NFIB-S lacks the DNA binding and protein in-
teraction domains (53), we investigated its ability
to interact with NFIC in MKs, given its pre-
viously hypothesized role in definitive postnatal
megakaryopoiesis (48). Cotransfection experi-
ments followed by immunoprecipitation showed
that the novel isoform, NFIB-S, lacked the ability
to interact with NFIC (Fig. 4C). To determine the
role of both NFIB and NFIC during megakar-
yopoiesis, we induced peripheral blood CD34+
cells to differentiate toward MKs and infected
them with pools of short hairpin RNA (shRNA)
lentiviruses targetingNFIB,NFIC, or anonsilencing
control. Knockdown of either gene resulted in a
marked reduction in differentiation towardMKs
as assessed by flow cytometry (Fig. 4D) and con-
firmed by morphological analysis (fig. S29). This
indicated that both NFIB-S and NFIC have an
essential role inmegakaryopoiesis despite the ab-
sence of a DNA binding domain in NFIB-S. Over-
expression of both NFIB-S and NFIC in CD34+
cells increased cell maturation (Fig. 4E, P = 0.001
and P = 0.014, respectively), measured as double
positivity for theMKmaturationmarkers CD41a
(ITGA2B) and CD42b (GP1BA) (54). In contrast,
overexpression of the canonical isoform, NFIB-L,
had no effect (Fig. 4E). These experiments in-
dicate that both NFIC and the novel isoform
NFIB-S, identified in our analysis, play a critical
interlinked role in the formation of MKs.
Discussion
Current knowledge of gene expression and func-
tion in hematopoiesis is mainly based on obser-
vations at gene level. However, it is the transcript,
rather than the gene, to which biological function
should be ascribed, either as protein-coding or
non–protein-coding RNA.
Here, RNA-seq of HSCs and seven progenitor
populations have enabled the identification, quan-
tification, and differential expression analysis of
cell type–specific transcript isoforms, novel and
unannotated splice junctions, and alternative
splicing events at a genome-wide level. Analysis
of lineage commitment events revealed a wealth
of previously undetectable transcript switching
and of shifts altering isoform usage ratio, with-
out appreciable changes at gene level, providing
evidence of additional layers of regulation in
cell fating.
Generating an atlas of splicing events allowed
us to explore the diversity and mechanisms be-
hind alternative splicing in human hematopoi-
esis as well as to contribute further to the human
genome functional annotation by reporting 7881
novel splice junctions specific to these rare cell
populations.
To demonstrate the importance of specific
isoforms in driving lineage-fating events, we
investigated the role of a TF highlighted by the
polytomous analysis. We envisage that integra-
tion of this Blueprint RNA-seq data set with the
deep catalogs generated by Blueprint and other
epigenome consortia will aid the annotation of
the functional genomic landscape of the hemato-
poietic system. This is essential in the continued
effort to interpret the functional consequences of
mutations in patients with rare hematological
disorders and supports the next enhancements
of personalized treatments for patients with
hematological malignancies.
Materials and methods
Progenitor cell purification
CB was collected after informed consent (ethical
approval REC 12/EE/0040), and mononuclear
cells were extracted. CD34+ cells were isolated
using the EasySep Human Progenitor Cell Enrich-
ment Kit with Platelet Depletion (STEMCELL
Technologies, Vancouver, Canada), stained using a
panel of antibodies, and flow-sorted to purify
HSC, MPP, CLP, CMP, MEP, and GMP cells that
were lysed in TRIzol reagent (Life Technologies,
Carlsbad, California).
Cell culture and purification
EBs and MKs were cultured from CD34+ cells
isolated from CB mononuclear cells with the hu-
man CD34 isolation kit (Miltenyi Biotec, Bergisch
Gladbach, Germany). For EBs, CD34+ cells were
cultured with erythropoietin, stem cell factor, and
interleukin-3 (IL-3) for 14 days. For MKs, CD34+
cells were cultured for 10 days in thrombopoietin
and IL-1b. Both populations were immunoselected
to >95% purity before lysis.
RNA-seq library preparation
and sequencing
RNA was extracted from TRIzol preparations.
One hundred picograms of RNA was used to gen-
erate poly(A)+ RNA libraries with the SMARTer
Ultra Low RNA and Advantage 2 PCR kits
(Clontech, Mountain View, California). Samples
were indexed with NEXTflex adapters (Bioo
Scientific, Austin, Texas), and 100-bp paired-end
sequencing was performed on Illumina HiSeq
2000 instruments with TruSeq reagents (Illumina,
San Diego, California).
Quality control, trimming, alignment,
and expression analysis
RNA-seq libraries were initially subjected to a
quality control step, where outliers were identi-
fied and discarded from further analysis on the
basis of the duplication rates and gene coverage.
Paired-end reads of the 25 independent samples
were trimmed for both PCR and sequencing
adapters with Trim Galore (55). Trimmed reads
were aligned to the Ensembl v70 human tran-
scriptome using Bowtie (56). Quantification of
gene and transcript expression was performed
with MMSEQ (26).
Differential expression analysis through
polytomous model classification
Significant differential expression was determined
withMMDIFF (30) at three different levels: gene,
transcript, and isoform usage (generically called
features). Polytomous classification was carried
out by first performing two-model comparisons
to calculate Bayes factors, B(0,m), between a com-
mon baseline model and models representing
the expression patterns of interest for a given
feature. In the baseline model, 0, the feature’s
mean expression level is the same in all cell types,
and in the alternative model, m, the mean ex-
pression level is allowed to differ according to
the desired pattern (for example, CMP = GMP ≠
MEP). Bayes’ theoremwas used to compute the
posterior probability that the truemodel g is equal
tom under the assumption that the alternative
models are exhaustive: P(g = m|x) = B(0, m) ×
P(g = m)/SB(0, m′) × P(g = m′), where x de-
notes the MMSEQ estimates for that feature.
For the transition from HSCs to MPPs, we
used a two-model comparison, where we used a
prior probability that the baseline model was
true of 0.9. This can be interpreted as a prior
belief that 10% of features are differentially ex-
pressed. Features with a posterior probability
for the alternative model above 0.5 (equivalent
to a Bayes factor threshold of 9, representing
strong evidence for the alternative model) and an
FPKM > 1 in at least two of the samples involved
were considered differentially expressed.
At each cell-fating point involving three cell
types, we studied all patterns of expression be-
tween the progenitor cell and its immediate
progeny. We classified feature expression pat-
terns according to five models. The simplest
model assumes that the mean expression level
is the same across cell types. The most complex
model assumes that the mean expression level
is different for each cell type. The remaining
three models assume that two of the three cell
types have the same mean expression level. We
specified a prior probability of 80% for the sim-
plest model and distributed the remaining prob-
ability evenly across the four alternative models.
The model with the highest posterior probability
was selected.
Gene set enrichment analysis
Gene and transcript sets derived from the poly-
tomous and the cell type–specific expression
analyses of the RNA-seq data were tested for gene
set enrichment with the goseq R/Bioconductor
package version 1.14.0 (57), which accounts for
the relationship between power of detection and
transcript length. All P values were corrected for
multiple testing using the Benjamini-Hochberg
method (58).
Selection of cell type–specific genes
and transcripts
We selected cell type–specific genes and tran-
scripts by performing a nine-model polytomous
comparison. The simplest model assumes that
the mean expression level is the same across cell
types. Each of the remaining eightmodels assumes
that the expression is the same across all cell types
except for one of the progenitors. We specified a
prior probability of 0.5 for the simplest model
and distributed the remaining probability evenly
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across the eight alternative models. Genes and
transcripts were required to have a posterior
probability > 0.5 and a fold change in expres-
sion> 1 tobedeclared cell type–specific. To compare
cell type–specific gene expression estimates be-
tween our RNA-seq data and publicly available
microarray data sets, we retrieved probe anno-
tations for the Illumina (16) and Affymetrix (14)
platforms from Ensembl v70.
Splice junction analysis
Identification of splice junctions for each sam-
ple was based on the alignment of the trimmed
reads to the human genome (GRCh37) with
three different aligners: GSNAP (59), STAR (60),
and GEM (61). Splice junctions were considered
for further analysis if supported by all three
aligners and by at least 10 reads in at least two
samples, where reads covered a minimum of
10 bp at both ends of the splice junction. We
defined a splice junction as unannotated if not
present in Ensembl v70. These were further
compared to the EST/mRNA data from UCSC
and the Illumina BodyMap 2.0 data set (35) to
identify novel splice junctions.
Splice site probability scores were extracted
from the GSNAP output. PhastCons conserva-
tion scores were used to plot evolutionary con-
servation in the 100 bp surrounding each splice
junction. Coding potential was estimated by
summing the number of possible stop codons in
exonic and intronic regions, in all reading frames
and in 100 bp flanking the unannotated splice
site. Shannon’s entropy (37) was calculated on the
basis of the read coverage of the splice junctions.
DSUwas identified with a beta-binomial model.
The characterization of the protein domains in
cassette exons with DSU was performed with
InterProscan 5 (62) to search for domains pre-
dicted by Pfam.
Validation of transcript isoform
expression and splicing events
To validate the quantification of transcript lev-
els determined by analysis of the RNA-seq data
with MMSEQ, we performed RT-PCR assays
with 40 transcript-specific assays and 5 positive
control assays in multiple cell subsets. Quantita-
tion of each transcript was performed in multi-
ple progenitor cell subsets with the BioMark HD
system (Fluidigm, San Francisco, California). Af-
ter requiring call quality scores >0.9 (Fluidigm
Real-Time PCR Analysis software, www.fluidigm.
com/software.html), 36 transcripts were analyzed.
For each probe,DDCq values were calculated with
the B2M transcript as control and the average
DDCq for MKs. Linear regression was then per-
formed between DDCq values and the correspond-
ing MMSEQ estimates relative to mean MK.
To validate progenitor-specific novel splice junc-
tions and exon-skipping events, we designed PCR
primers to amplify 30 junctions identified byRNA-
seq. PCR was performed on pools of the RNA-seq
libraries. PCR products were run on agarose gel
and imaged, and densitometry was performed.
PacBio libraries were generated (Pacific Biosci-
ences, Menlo Park, California) from cDNA obtained
by reverse transcription of 10 ng of MK_3 total
RNA and sequenced in five SMRT cells on the
PacBio RSII. SMRT Pipe and ICE were used to
filter reads to generate consensus sequence clusters
that were mapped to the reference human ge-
nome (GRCh37) using GMAP.
Enrichment analysis of RNA-binding
motifs around cassette exons
Motif enrichment analysis of 102 RNA-binding
motifs (41) was performed on DSU cassette exons
(FDR < 0.05 and usage proportion change > 0.05)
over three genomic regions: upstream intronic
(300 bp), exonic, and downstream intronic (300 bp).
Enrichment and depletion of RNA-binding mo-
tifs was determined with cumulative hypergeo-
metric testing, and P values were corrected for
multiple testing.
Cloning, shRNA, lentivirus production,
and transduction
TRC shRNA lentivirus targeting NFIB and NFIC
and a nonsilencing control were purchased from
ThermoScientificOpenBiosystems (LittleChalfont,
UK). NFIB full length and NFIC cDNA were
cloned into pWPI TAP-tagged vector. Packaging
was performed in 293T cells, and viral stocks were
titrated and quantified using qPCR and, for pWPI,
using qPCR and green fluorescent protein FACS.
CD34+ cells were purified from NHS Blood and
Transplant apheresis filters, as above (Miltenyi), and
then infected with lentiviral particles in the pres-
ence of polybrene, in medium supplemented with
thrombopoietin and IL-1b. On day 2, medium was
replaced and cells were cultured toward MKs. At
day 10, MKs were counted and assessed by mor-
phology and flow cytometry for maturation.
Transfections, immunoprecipitations,
and Western blots
To detect protein-protein interactions, NFI pro-
teins were expressed by cotransfection in 293T
cells and immunoprecipitated with an anti-Flag
antibody. Western blots were probed with NFIB,
NFIC, and b-tubulin.
Data presentation
River plots were generated with the ggplot2 R
package (version 0.9.3.1), which was obtained from
Bioconductor (www.bioconductor.org/). Heat maps
were generatedwithboth thegplots (version 2.13.0)
and pheatmap (version 0.7.7) R packages, which
were both obtained from CRAN (http://cran.
r-project.org/). For sequence logos of the splice site
motifs,weused seqLogoRpackage (version 1.30.0)
available from Bioconductor. The IGV genome
browser (version 2.3.34) was used for visualization
(www.broadinstitute.org/igv/). For further details,
please refer to the supplementary materials.
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